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Abstract  27 
Activation of free fatty acid receptor (FFAR)2 and FFAR3 via colonic short-chain fatty acids, 28 
particularly propionate, are postulated to explain observed inverse associations between dietary 29 
fiber intake and body weight. Propionate is reported as the predominant colonic fermentation 30 
product from L-rhamnose, a natural monosaccharide that resists digestion and absorption reaching 31 
the colon intact, while effects of long-chain inulin on appetite have not been extensively 32 
investigated. In this single-blind randomized crossover study, healthy unrestrained eaters (n=13) 33 
ingested 25.5 g/d L-rhamnose, 22.4 g/d inulin or no supplement (control) alongside a standardized 34 
breakfast and lunch, following a 6-d run-in to investigate if appetite was inhibited. Postprandial 35 
qualitative appetite, breath hydrogen, and plasma glucose, insulin, triglycerides and non-esterified 36 
fatty acids were assessed for 420 min, then an ad libitum meal was provided. Significant treatment x 37 
time effects were found for postprandial insulin (P=0.009) and non-esterified fatty acids (P=0.046) 38 
with a significantly lower insulin response for L-rhamnose (P=0.023) than control. No differences 39 
between treatments were found for quantitative and qualitative appetite measures, although 40 
significant treatment x time effects for meal desire (P=0.008) and desire to eat sweet (P=0.036) 41 
were found. Breath hydrogen was significantly higher with inulin (P=0.001) and L-rhamnose 42 
(P=0.009) than control, indicating colonic fermentation. These findings suggest L-rhamnose may 43 
inhibit postprandial insulin secretion, however neither L-rhamnose or inulin influenced appetite.   44 
 45 
Highlights: 46 
• Postprandial effects of supplementation with inulin and L-rhamnose were investigated 47 
• Neither inulin nor L-rhamnose influenced subjective or quantitative appetite measures 48 
• L-rhamnose supplementation did inhibit insulin production postprandially 49 
 50 
Keywords: Appetite; satiety; postprandial insulin; inulin-type fructans; short-chain fatty acids 51 
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 52 
Abbreviations: Area under curve, AUC; Energy intake, EI; Free fatty acid receptor, FFAR; 53 
Glucagon-like receptor-1, GLP-1; Homeostasis Assessment Model, HOMA; Incremental area under 54 
curve, iAUC; L-rhamnose, L-Rha; Peptide YY, PYY; Short-chain fatty acid, SCFA;  Visual 55 
analogue scale, VAS 56 
 57 
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Introduction  59 
Inverse associations between dietary fiber intake and body weight (Du, et al., 2010; Howarth, 60 
Huang, Roberts, & McCrory, 2005), hunger and energy intake (EI) following non-digestible 61 
carbohydrate ingestion in randomized controlled trials (Wanders, et al., 2011), indicate dietary fiber 62 
and other non-digestible carbohydrates may have a role in the prevention and treatment of obesity. 63 
Postulated mechanisms include an increased viscosity of intestinal contents (Kristensen & Jensen, 64 
2011), a reduced energy density due to the bulking effect of non-digestible carbohydrates (Burton-65 
Freeman, 2000), and an inhibition of EI arising from effects of non-digestible carbohydrate on 66 
satiation and satiety (Burton-Freeman, 2000), possibly mediated by actions of colon derived short-67 
chain fatty acids (SCFA). 68 
Physiological serum SCFA concentrations are low, in the region of 1, 2 and 65 µmol/L for 69 
fasting serum butyrate, propionate and acetate  (Fernandes, Vogt, & Wolever, 2011). Postprandially 70 
SCFA concentrations appear to increase significantly in response to ingestion of some non-71 
digestible carbohydrates including resistant starch (Robertson, Bickerton, Dennis, Vidal, & Frayn, 72 
2005). Physiological SCFA concentrations have been shown to activate two G-protein coupled 73 
receptors, free fatty acid receptor (FFAR) 2 and FFAR3 (Brown, et al., 2003; Le Poul, et al., 2003), 74 
with propionate reported as the most potent agonist (Le Poul, et al., 2003). FFAR2 and FFAR3 are 75 
co-localized in colonic enteroendocrine L-cells with peptide YY (PYY) and glucagon-like peptide 1 76 
(GLP-1) (Karaki, et al., 2006; Karaki, et al., 2008; Tazoe, et al., 2009), both hormones which are 77 
postulated to play roles in the physiological regulation of appetite (Hussain & Bloom, 2013; Lean & 78 
Malkova, 2015). In vivo administration of SCFA increases plasma PYY in rats (Cherbut, et al., 79 
1998; Psichas, et al., 2015) and pigs (Cuche, Cuber, & Malbert, 2000), and of propionate increases 80 
GLP-1 and PYY via FFAR2 activation in rodents (Psichas, et al., 2015). In vitro and in vivo 81 
evidence in rodents further indicates SFCA-induced FFAR2 and FFAR3 activation upregulates 82 
leptin expression in adipose tissue (Covington, Briscoe, Brown, & Jayawickreme, 2006; Xiong, et 83 
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al., 2004). Thus SCFA, particularly propionate, may be postulated to influence energy homeostasis 84 
and insulin secretion.  85 
 L-Rhamnose (L-Rha), a natural monosaccharide that resists digestion and absorption 86 
reaching the colon intact (J.A. Vogt, Pencharz, & Wolever, 2004), shows promise as a suitable 87 
candidate to investigate effects on colonic propionate on appetite. Propionate is reported as the 88 
primary SCFA produced during fermentation of L-Rha in vitro (Fernandes, Rao, & Wolever, 2000), 89 
and L-Rha ingestion increased serum propionate concentrations in humans acutely (J. A. Vogt, et 90 
al., 2004) and chronically (J. A. Vogt, et al., 2004). Effects of L-Rha ingestion on metabolic 91 
response have been previously investigated (J. Vogt, Ishii-Schrade, Pencharz, & Wolever, 2004; J. 92 
A. Vogt, et al., 2004); albeit not extensively, however effects on appetite have not.  93 
Effects of supplementing with inulin-type fructans on appetite are more extensively 94 
investigated; however, results are contradictory due to variable dosages, differing types of inulin-95 
type fructans and limitations in study design (reviewed by (Darzi, Frost, & Robertson, 2011)). 96 
While a number of studies have investigated effects on appetite of short-chain inulin-type fructans, 97 
also termed oligofructose and fructooligosaccharides (for example (Hess, Birkett, Thomas, & 98 
Slavin, 2011; Parnell & Reimer, 2009; Pedersen, et al., 2013; Peters, Boers, Haddeman, Melnikov, 99 
& Qvyjt, 2009; Verhoef, Meyer, & Westerterp, 2011)), few investigations of long-chain inulin 100 
effects exist (Archer, Johnson, Devereux, & Baxter, 2004; Karalus, et al., 2012; Tarini & Wolever, 101 
2010). The present study therefore aimed to investigate the acute effects of providing L-Rha or 102 
long-chain inulin, following a 6-d run-in, on postprandial appetite and metabolite concentrations 103 
compared to control (no supplement).  104 
  105 
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Methods  106 
Participants 107 
Healthy, non-smoking unrestrained eaters 18-55 y were recruited via e-mail advertisement at the 108 
University of Surrey and attended the Clinical Investigation Unit (CIU) in a fasted state for 109 
screening. Inclusion criteria were BMI between 19-26 kg/m2, fasting blood glucose <6.0 mmol/l, 110 
weight stable for at least 3 months, non-smoker and reported habitual alcohol intake ≤20 units. 111 
Exclusion criteria included following a weight reducing diet, presence of gastrointestinal, endocrine 112 
or cardiovascular disorders, history of depression, eating disorders or substance abuse, pregnancy or 113 
lactation, taking regular medication (except birth control medication), and high dietary restraint 114 
(score ≥3.5 on the Dutch Eating Behaviour Questionnaire restraint scale (Van Strien, Frijters, 115 
Bergers, & Defares, 1986)). The study was conducted according to the Declaration of Helsinki and 116 
all procedures involving human participants were approved by the University of Surrey Ethics 117 
Committee (Ref: EC/2008/53/FHMS). Participants gave written informed consent.  118 
 119 
Study Protocol 120 
This single-blind 3-way randomized crossover study was conducted from September 2008 to May 121 
2009. Participants commenced 1-wk study periods during which L-Rha, long-chain inulin or control 122 
(no supplement) were consumed an order randomly assigned using www.randomizer.org. The 123 
condition randomized to was concealed by providing participants with ready prepared jelly (Jell-O) 124 
and mousse containing the supplement or control (no supplement) to disguise the treatment.  Each 125 
study period comprised a 6-d run-in with a study day at the CIU on Day 7 and were separated by a 126 
washout period of ≥1-wk.  Prior to commencing the study, all participants who had not previously 127 
participated in an appetite study attended an initial study morning at the CIU to familiarise with the 128 
techniques being used. To control for effects of hormonal variations throughout the menstrual cycle 129 
(Asarian & Geary, 2013), female participants not using birth control medication attended the study 130 
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day at approximately the same point of the menstrual cycle for each study day during the mid-131 
follicular phase (between days 8 and 12). Participants were informed that the study aimed to 132 
compare the effects of two fiber supplements compared to a placebo (no fiber) on appetite and 133 
metabolic response.  134 
 135 
Six day run-in  136 
The supplement dosages used were based on the reported dose used in previous investigations of L-137 
Rha (J. A. Vogt, Ishii-Schrade, Pencharz, Jones, & Wolever, 2006; J. A. Vogt, et al., 2004), with 138 
the equivalent inulin dose calculated to be matched by pentose/hexose equivalents. The target dose 139 
of 25.5 and 22.4 g/d for L-Rha and inulin was reached by Day 4, increasing from one-third, half and 140 
two-thirds target dose during Days 1-3. The supplement (inulin or L-Rha) or control (no 141 
supplement) was provided within two portions of jelly (Hartleys Sugar Free Jelly) during run-in to 142 
be consumed alongside participants’ usual diet. Sugar free jelly was chosen as the vehicle to 143 
provide the supplement, as it did not contribute greatly to the EI, it disguised the supplement or 144 
control, and made it easy for the participant to consume the supplement, as no additional 145 
preparation was required. The jellies were collected by or were dropped off to participants every 146 
few days. Compliance, gastrointestinal symptoms and the taste of the jellies were assessed using a 147 
daily monitoring diary, and a 4-day food diary was completed from Days 3 to 6 using household 148 
measures. Gastrointestinal symptoms (stomach pain, diarrhoea, constipation, belching, flatulence, 149 
nausea, acid regurgitation, heartburn and bloating) were monitored on a five point scale (1: none, 3: 150 
moderate, 5: debilitating), and taste was assessed on a nine point Likert Scale.. 151 
 152 
Study day (Day 7) 153 
Participants arrived at the CIU in a fasted state after consuming a standard low fiber meal the 154 
previous evening and avoiding alcohol and unaccustomed exercise for 24-h. Participants were 155 
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required to stay in the CIU for the entire study duration and water was provided ad libitum.  Upon 156 
arrival anthropometric measurements were taken and an intravenous cannula was inserted into an 157 
antecubital vein. Two fasting blood samples were taken 30 min and 5 min before breakfast, and 158 
hydrogen concentrations in expired breath were measured using a Gastrolyser 2 portable hand held 159 
breath hydrogen monitor (Bedfont Scientific Ltd, Rochester, UK). Following each baseline blood 160 
and breath sample appetite was subjectively assessed by 100 mm visual analogue scale (VAS) 161 
questionnaires for fullness, hunger, prospective food consumption, desire to eat meal / snack / sweet 162 
/ savoury / salty / fatty and nausea as previously described (Flint, Raben, Blundell, & A., 2000). 163 
Gastrointestinal symptoms (flatulence, diarrhoea, bloating, belch/burp, stomach discomfort, urge to 164 
defacate and heartburn) were also assessed by 100 mm VAS following the first baseline blood 165 
sample.   166 
A standard mixed breakfast and lunch (described below) were provided at t=0 min and 167 
t=180 min, and consumed within 15 min. A mousse was provided alongside breakfast and lunch 168 
containing two-thirds and one-third of the daily target supplement dose, respectively, or no 169 
supplement (control). The taste of the mousse was rated after each meal using 100mm VAS. 170 
Following each meal blood was sampled every 15 min for the first hour, then half-hourly, VAS 171 
were completed after blood samples to assess appetite half-hourly and to assess gastrointestinal 172 
symptoms hourly. Breath was sampled hourly for the first hour and half-hourly thereafter.  173 
The cannula was removed at t=420 min (240 min following lunch) after which participants 174 
were seated in individual booths at t=420 min and served an ad libitum homogenous pasta meal in a 175 
quantity exceeding usual portion sizes and instructed to eat until they were “comfortably full”, as 176 
previously conducted by our group (Bodinham, Frost, & Robertson, 2010; Darzi, Frost, & 177 
Robertson, 2012). Participants were free to leave and asked to complete a food diary for the 178 
remainder of the day which, in combination with intake at breakfast, lunch and the ad libitum test 179 
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meal, was used to determine overall 24 h intake.  Dietary analysis was performed using WinDiets 180 
Professional Version 2005 (Robert Gordan University, Aberdeen, UK). 181 
 182 
Test products and study day test meals 183 
The supplements used were Orafti Beneo Inulin HP (DKSH Great Britain Limited, Wimbledon, 184 
UK), a high degree of polymerisation inulin (average degree of polymerisation ≥ 23), and food 185 
grade 98 % L-(+)-Rhamnose Monohydrate (Vitanutrition Ltd, Co Dublin, Ireland).  During the 186 
control leg, only the carrier product was consumed. 187 
On study days the supplement under investigation was incorporated into a mousse (Angel 188 
Delight, Premier Foods Group, made using semi-skimmed milk), as used previously by our group 189 
(Bodinham, et al., 2010). Two-thirds of the daily dose (16.8g L-Rha or 14.9 g inulin HP) was 190 
provided at breakfast, and one-third (8.4 g L-Rha or 7.5 g inulin HP) was provided at lunch.  For 191 
control, the mousse with no added supplement was provided.  To enhance compliance, participants 192 
were given a choice of four mousse flavours and were given the same flavour on each study day.  193 
The standard mixed breakfast supplied on the study day comprised croissants (66 g) with 194 
strawberry or plum jam (28 g), the supplement-containing mousse and either water (250 g) or sugar-195 
free cordial (42 g cordial and 208 g water).  The same jam and drink was on each study day.  The 196 
breakfast supplied 2074 kJ, 10.5 g CHO, 36.4 g protein and 21.1 g fat when made using strawberry 197 
jam and chocolate mousse. 198 
The standard study day lunch comprised ham, chicken or cheese sandwiches, crisps, the 199 
supplement-containing mousse and either water or sugar-free cordial.  The same sandwich filling 200 
and drink was supplied on each study day.  On the first study day participants were provided eight 201 
sandwich quarters and 20 g crisps and were asked to consume at least 4 full sandwich quarters and 202 
as many crisps as they would like.  On subsequent study days participants were required to consume 203 
the same number of sandwiches and amount of crisps as consumed on the first study occasion, as 204 
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previously reported (Weststrate & van Amelsvoort, 1993) and used by our group (Bodinham, et al., 205 
2010).   206 
All food ingredients were weighed to the nearest 1 g except the Angel Delight and non-207 
digestible carbohydrate supplements which were weighed to the nearest 0.1 g. 208 
 209 
Ad libitum test meal 210 
The ad libitum test meal comprised a homogenous pasta dish made following a standard recipe of 211 
Tesco Fusilli Pasta Twists (400 g dry weight) mixed with Ragu Original Pasta Sauce (500 g), Tesco 212 
Mild Cheddar (100 g) and Tesco Vegetable Oil (30 g).  The dish supplied 9750 kJ, 81.5 g protein, 213 
339.1 g carbohydrate, 70.0 g fat and 15.9 g fiber and had a mean weight of 1520 ± 53 g and energy 214 
density of 6.4 ± 0.2 kJ/g.  The weight and energy density varied due to differing amounts of water 215 
absorbed by the pasta during cooking which was accounted for when calculating EI. The dish was 216 
weighed before and after serving to determine intake. 217 
 218 
Biochemistry 219 
Venous blood samples were centrifuged at 1750 g for 10 min and plasma aliquots were stored at -20 220 
°C until analysis.  Samples were batch analysed with samples from the same participant in the same 221 
batch to minimise inter-assay variability.  Plasma glucose, TG, non-esterified fatty acids (NEFA) 222 
and total and HDL cholesterol concentrations were measured using commercial kits for the ILAB 223 
650 analyzer (Instrumentation Laboratory, Milan, Italy), with an inter-assay CV of <2 %. Plasma 224 
insulin concentrations were analyzed by radioimmunoassay using a commercial kit (Millipore, St. 225 
Charles, Missouri), with an inter- and intra-assay CV <10 %. Serum SCFA were analyzed by gas 226 
chromatography as previously described (Bodinham, et al., 2014; J. A. Vogt, et al., 2004).  227 
 228 
Insulin sensitivity 229 
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Insulin sensitivity parameters were assessed on the study day (Day 7). Fasting insulin sensitivity 230 
was assessed by Homeostasis Assessment Model (HOMA) using the HOMA2 Calculator Version 231 
2.2 (University of Oxford, Oxford, UK) to estimate steady state β-cell function, insulin sensitivity 232 
and insulin resistance from fasting plasma glucose and insulin concentrations as previously 233 
described (Levy, Matthews, & Hermans, 1998; Matthews, et al., 1985; Wallace, Levy, & Matthews, 234 
2004). Postprandial insulin sensitivity was assessed using the minimal model index method as 235 
described by (Caumo, Bergman, & Cobelli, 2000).  236 
 237 
Calculations and statistical analysis 238 
Area under curve (AUC) for postprandial data (appetite and gastrointestinal VAS ratings, plasma 239 
metabolites and SCFA, and breath hydrogen) was calculated by the trapezoidal rule and incremental 240 
AUC (iAUC) was also determined to allow for baseline concentration differences. Statistical 241 
analyses were conducted using SPSS for Windows (version 21, SPSS Inc, Chicago, IL). Normality 242 
was tested using the Kolmogorov-Smirnov test. Differences in the effects of treatment on dietary 243 
intake, fasting breath hydrogen, AUC and iAUC of postprandial data, gastrointestinal symptom 244 
mean daily ratings, HOMA and postprandial insulin sensitivity estimates were investigated by one 245 
way repeated measures ANOVA with post-hoc Bonferonni or Friedman test with post-hoc 246 
Wilcoxon signed ranks test as appropriate. Postprandial data was also analysed by two-way 247 
(treatment x time) repeated measures ANOVA. Data are presented as mean ± SD unless otherwise 248 
stated and differences were considered significant at p≤0.05 except post-hoc Wilcoxon, where 249 
significance was set at p≤0.0167 (=0.05/3). 250 
The sample size was based on the chronic crossover study of Vogt et al in which a 251 
significant increase in serum propionate was found with L-rhamnose supplementation in 11 252 
participants  (J. Vogt, et al., 2004). As we wanted to investigate if a rise in serum propionate would 253 
drive effects on appetite, we aimed to recruit at least 11 participants to investigate these 254 
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mechanisms. A power analysis was performed retrospectively in which we found 13 participants 255 
would have given an 80 % power of detecting a difference in actual food intake of 749 kJ, with a 256 
measured SD of the response to L-rhamnose treatment of 845 kJ. As the actual net effect of the L-257 
rhamnose ingestion was a reduced food intake of only 150 kJ, with 5/13 participants eating more 258 
following the L-rhamnose than following control, 250 participants would have been required at 259 
80% power in order to achieve statistical significance, which far exceeds other studies of this nature 260 
by several fold. The lack of statistical effect is therefore likely to be due to a lack of biological 261 
effect rather than simply a power issue. 262 
 263 
264 
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Results  265 
 266 
Thirteen participants aged 19-32 y with BMI and DEBQ restraint score ranging from 19.5 to 24.7 267 
kg/m2 and 1.1 to 3.6 respectively completed the study. Of the eight female participants, seven were 268 
using birth control medication (Table 1). Results are presented for the run-in period (days 1 to 6) 269 
and for the study day (day 7).  270 
 271 
Quantitative appetite assessment 272 
No differences between treatments were found for mean daily energy and macronutrient intake 273 
during the days 3 to 6 of the run-in period, or for 24-h dietary intake on the study day (Table 2). 274 
Mean ad libitum EI of the homogenous pasta meal served at 420 min on the study day did not differ 275 
between control, inulin or L-Rha  (4202 ± 1666, 4089 ± 1680 and 4053 ± 1538 kJ respectively). 276 
 277 
Qualitative appetite assessment 278 
No treatment or treatment x time effects were found for postprandial VAS appetite ratings on the 279 
study day for hunger (Figure 1A), fullness, prospective consumption or desire to eat a snack, and 280 
AUC did not differ between treatments. A treatment x time interaction was found during the 281 
morning (0-180 min) for meal desire (F(12,144) = 2.36, P=0.008) (Figure 1B) and during the 282 
afternoon (180-420 min) for the desire to eat sweet (F(16,192) = 1.78, P=0.036), but no difference 283 
between treatments was found by post-hoc analysis.  284 
 285 
Breath hydrogen concentrations 286 
Significant treatment effects were found for fasting and postprandial AUC breath hydrogen 287 
concentrations (χ2(2) = 14.3, P=0.001 and χ2(2) = 15.9, P<0.001 respectively) (Figure 1C). Fasting 288 
concentrations were significantly higher following inulin than L-Rha (T = 89, r = -0.49, P=0.002) 289 
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and control (T = 82, r = -0.41, P = 0.011), and the AUC was significantly higher for inulin (T = 91, 290 
r = -0.51, P=0.001) and L-Rha (T = 83, r = -0.42, P = 0.009) than control.   291 
 292 
Postprandial metabolites 293 
For postprandial insulin concentrations (Figure 2A) treatment effects approaching significance 294 
following breakfast (F(2,24) = 3.38, P=0.051) and significant treatment x time effects following 295 
breakfast (F(16,192) = 1.88, P=0.024), lunch (F(18,216) = 1.81, P=0.026) and during the entire 296 
study day (F(34, 408) = 1.71, P=0.009) were found.  The iAUC following breakfast and during the 297 
entire study day were significantly lower for L-Rha than control (T = 9, r = -0.41, P=0.011 and T = 298 
13, r = -0.36, P=0.023 respectively) (Figure 2B). No treatment or treatment x time interactions for 299 
postprandial glucose or triglycerides and no treatment effects for postprandial NEFA concentrations 300 
were found, although there was a significant treatment x time interaction (F(16,192) = 1.72, 301 
P=0.046) following lunch for NEFA.   302 
 303 
Serum SCFA 304 
No treatment or treatment x time interactions or differences between AUC or iAUC were found 305 
postprandially and no differences between fasting concentrations were found between treatments 306 
for propionate, acetate or butyrate (Figure 3).  307 
 308 
Insulin sensitivity  309 
Neither fasting insulin sensitivity, cell function and insulin resistance as estimated by HOMA nor 310 
postprandial insulin sensitivity estimated using the minimal model method were found to differ 311 
between treatments (data not shown). 312 
 313 
Gastrointestinal symptoms 314 
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During run-in, the mean daily flatulence ratings during days 4 to 6 (when participants were 315 
consuming the target dose of supplement) were significantly influenced by treatment (χ2(2) = 8.6, P 316 
= 0.014). Scores were significantly higher during inulin treatment than control (T = 36, r = -0.40, 317 
P=0.012) and L-Rha (T = 6, r = -0.35, P=0.028), with mean scores of 2.2 ± 0.9, 1.4 ± 0.6 and 1.5 ± 318 
0.5 respectively. On the study day (day 7), the AUC for the urge to defacate was significantly 319 
higher during L-Rha treatment than control (T = 84, r = -0.43, P =0.007) (data not shown).  None of 320 
the other gastrointestinal symptoms was significantly influenced by treatment during run-in or on 321 
the study day. 322 
 323 
Taste ratings 324 
Mean daily ratings of the taste of the jellies supplied during the run-in period did not differ between 325 
treatments. On the study day, treatment significantly influenced the rated taste of the mousse at 326 
breakfast (F(2,24) = 5.49, P=0.011), with the lowest VAS score for L-Rha, followed by inulin and 327 
the highest for control (58 ± 21, 73 ± 20 and 75 ± 21 mm respectively), but not at lunch.     328 
 329 
Discussion  330 
Our findings suggest supplementation with 25.5 g/d L-Rha or 22.4 g/d inulin HP significantly 331 
influence postprandial plasma insulin (P=0.009) and plasma NEFA (P=0.046, following lunch) 332 
responses. The lowest response for both was with L-Rha treatment, previously reported to enhance 333 
serum propionate concentrations (J. A. Vogt, et al., 2004), which was to a significant level for 334 
plasma insulin in comparison to control. This was accompanied by significant increases in 335 
postprandial breath hydrogen concentrations (P<0.001) following L-Rha and inulin ingestion in 336 
comparison to control, indicating colonic fermentation occurred, although serum SCFA 337 
concentrations were not increased alongside this. However quantitative and subjective appetite 338 
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measures were not altered with supplementation, except desire to eat (P=0.008) during the morning, 339 
suggestive of a lack of effect of these non-digestible carbohydrate supplements on appetite.  340 
The observed suppression of postprandial plasma insulin following L-Rha may have arisen 341 
via propionate-mediated activation of FFAR2 and/or FFAR3 in colonic mucosa initiating ileal brake 342 
mechanisms via PYY and GLP-1 production (Karaki, et al., 2006; Karaki, et al., 2008; Tazoe, et al., 343 
2009). However, unlike previous reports (J. A. Vogt, et al., 2004) we found no impact on serum 344 
propionate concentrations following L-Rha ingestion. Previous studies found L-Rha 345 
supplementation did not alter postprandial insulin or NEFA responses (J. A. Vogt, et al., 2006), in 346 
contrast with the present study, nor postprandial plasma glucose and triglyceride responses (J. A. 347 
Vogt, et al., 2006; J. A. Vogt, et al., 2004), in common with the present study. A limitation of 348 
previous investigations is that glucose was used as control, which could confound interpretation, 349 
and blood samples were collected only hourly, therefore potentially missing postprandial effects of 350 
these metabolites, which change rapidly following a meal. By contrast the present study examined 351 
effects of L-Rha on postprandial metabolites with regular blood sampling and an appropriate 352 
control, explaining why our results reveal novel findings in contrast to those before. The effects we 353 
observed did not appear to be related to insulin sensitivity, as we found no influence of L-Rha or 354 
inulin on estimates of fasting and postprandial insulin sensitivity.  355 
To our knowledge this is the first study to investigate effects of L-Rha on appetite. In 356 
contrast to the lack of effect on appetite in the present study, colonic delivery of propionate while 357 
tethered to inulin significantly increased postprandial PYY and GLP-1 responses and reduced EI 358 
acutely and weight gain chronically (Chambers, et al., 2014). Possibly greater colonic 359 
concentrations of propionate were achieved with this novel non-digestible carbohydrate than via L-360 
Rha, arguably a natural source of propionate, in the present study. This is supported by our finding 361 
that serum propionate concentrations were not altered by treatment. Further, in contrast to the 362 
present study, the novel non-digestible carbohydrate did not significantly alter postprandial insulin 363 
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concentrations (Chambers, et al., 2014). Possibly the effects on insulin following L-Rha 364 
supplementation may not be potentiated by the colonic generation of propionate, but by some other, 365 
as yet unknown, mechanism.  366 
Relatively few previous investigations have reported on effects on appetite of long-chain 367 
inulin (Archer, et al., 2004; Karalus, et al., 2012; Tarini & Wolever, 2010) like that used in the 368 
present study, with the majority of studies reporting on supplementation with short-chain inulin-369 
type fructans (for example (Hess, et al., 2011; Parnell & Reimer, 2009; Pedersen, et al., 2013; 370 
Peters, et al., 2009; Verhoef, et al., 2011)). Long-chain inulin has the benefit of being associated 371 
with less adverse gastrointestinal symptoms than the short-chain counterpart (Bonnema, Kolberg, 372 
Thomas, & Slavin, 2010; Bruhwyler, Carreer, Demanet, & Jacobs, 2009), providing a rationale to 373 
investigate effects on long-chain inulin. Indeed in the present study we found that gastrointestinal 374 
symptoms were not adversely affected by long-chain inulin supplementation, except significantly 375 
higher flatulence scores during run-in, and even then the mean flatulence symptom score with inulin 376 
treatment of 2.2 ± 0.9 (scored on a 9-point Likert Scale) remained relatively low.  377 
We did not find any significant effects of supplementation with long-chain inulin on 378 
qualitative or quantitative appetite measures, on postprandial metabolites or on serum SCFA 379 
concentrations. The lack of effect on postprandial serum SCFA in conjunction with a higher breath 380 
hydrogen response has been previously reported following consumption of long-chain inulin 381 
(Fernandes, et al., 2011). In common with our findings, a previous trial in 22 unrestrained females 382 
found acute ingestion of 10 g long-chain inulin within a chocolate crisp bar did not alter qualitative 383 
or quantitative appetite measures in comparison to a control bar (Karalus, et al., 2012). By contrast 384 
24 g long-chain inulin used as a fat-replacer in sausage patties significantly reduced 24-h EI in 385 
comparison to a full fat patty in an acute meal challenge in healthy participants (n=33), although 386 
rated satiety was not altered, and ad libitum EI was not investigated (Archer, et al., 2004). However, 387 
the control had a higher fat and therefore energy content than the inulin preload making 388 
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interpretation difficult (Archer, et al., 2004). In our study the control was energy and macronutrient 389 
matched to the investigative products. Higher plasma GLP-1 concentrations at 30 min and reduced 390 
ghrelin concentrations at 270 and 360 min were reported following an acute meal challenge in 12 391 
healthy participants with 24 g inulin plus 56 g high-fructose corn syrup in comparison to 56 g high-392 
fructose corn syrup and 80 g high-fructose corn syrup mixed into a drink (Tarini & Wolever, 2010). 393 
However as effects on GLP-1 were seen so early on postprandially this is suggestive the 394 
observation is not linked to colonic fermentation. Overall the evidence does not strongly support a 395 
role for long-chain inulin in influencing appetite, although studies are limited by participant 396 
numbers. 397 
The majority of previous studies investigating metabolic effects of long-chain inulin have 398 
investigated fasting rather than postprandial effects, therefore there is a paucity of comparative 399 
studies. In an acute meal challenge, glucose and insulin responses did not differ significantly 400 
following supplementation with 24 g inulin + 56g high-fructose corn syrup mixed into a drink in 401 
comparison to 56 g and 80 g high-fructose corn syrup in healthy participants (n=12) (Tarini & 402 
Wolever, 2010), agreeing with findings from the present study. Similarly there was no difference in 403 
postprandial glucose and insulin in response to an oral glucose tolerance test in men classified at 404 
higher risk of cardiovascular disease (n=10) following consumption of 15 g inulin per day within 405 
bread rolls for 4 weeks in comparison to nutrient-matched control bread rolls (Tripkovic, Muirhead, 406 
Hart, Frost, & Lodge, 2014).  407 
The present study had a number of limitations which need to be acknowledged when 408 
interpreting findings. Ideally the study would have been double blinded, however as there was only 409 
a single investigator (JD) to conduct the study this was not possible. The study included relatively 410 
few participants, however effects on food intake were so negligible retrospective power analysis 411 
suggested 250 participants would be required for statistical significance, which is far greater than in 412 
other studies of this nature. Thus the lack of effect is likely due to a lack of biological effect rather 413 
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than simply a power issue. We chose to include female participants in order to be more 414 
representative of the general population. However whilst every effort was made to control for 415 
hormonal fluctuations, this will likely have added some variability. Participants were informed of 416 
the broad purpose of the study, which may have impacted behavior, however every effort was made 417 
to maintain a uniform protocol for each condition. We did not assess if participants were aware of 418 
the study hypotheses or if they were able to accurately report any differences in the protocol 419 
according to the condition they were randomised to. As water was supplied ad libitum to be more 420 
reflective of free-living conditions, this may have impacted on appetite, an effect we could not 421 
assess as water intake was not measured. 422 
In conclusion, the present investigation found neither inulin HP nor L-Rha influenced 423 
appetite, and inulin HP did not influence postprandial metabolic responses. However L-Rha 424 
appeared to inhibit postprandial insulin secretion and also NEFA, possibly via propionate-mediated 425 
colonic FFAR2 and/or FFAR3 actions, although serum propionate was not significantly altered and 426 
insulin was not inhibited following ingestion of propionate tethered to inulin. This suggests that the 427 
mechanism underlying our findings may not be mediated by propionate as originally hypothesized, 428 
which warrants further investigation.  429 
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TABLE 1 Baseline characteristics of participants at screening. Data shown as mean ± SD and n 585 
(%). 586 
 587 
 Overall (n=13) Male (n=5) Female (n=8) 
Age / y 23 ± 4 23 ± 3 23 ± 4 
BMI / kgm-2 22.1 ± 1.6 23.0 ± 1.5 21.5 ± 1.5 
Waist circumference / cm 75.5 ± 6.9 82.9 ± 3.1 70.5 ± 2.3 
Body fat / % 21.9 ± 6.5 15.5 ± 3.4 26.0 ± 4.1 
Systolic BP / mmHg 115 ± 9 120 ± 7 110 ± 8 
Diastolic BP / mmHg 68 ± 8 67 ± 6 69 ± 9 
Fasting blood glucose / mmol/L 4.3 ± 0.5 4.4 ± 0.5 4.2 ± 0.4 
DEBQ Restraint Score 2.1 ± 0.8 2.2 ± 0.9 2.1 ± 0.7 
Using birth control / n (%)   7 (88 %)# 
 588 
Abbreviations: DEBQ, Dutch Eating Behaviour Questionnaire Restraint Score, BMI, body mass 589 
index, BP, blood pressure. 590 
#
  5 using combined pill, 1 using contraceptive implant, 1 using progesterone-only pill 591 
 592 
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TABLE 2 (A) Mean daily intake during last 4-d of run-in period, and (B) 24-h intake on study day, 594 
including all provided foods during study and additional intake for the remainder of the day in 13 595 
healthy men and women during supplementation with inulin, L-Rhamnose (L-Rha) or control. No 596 
differences were found between treatments. Analyses carried out by one-way within participants 597 
repeated measures ANOVA or Friedman’s as appropriate. Data shown as mean ± SD.  598 
 599 
 
 
(A) Daily intake during run-in (B) 24-h intake on study day 
 Control Inulin L-Rha Control Inulin L-Rha 
Energy / kJ 9078 ± 
1857 
8730 ± 
2232 
8691 ± 
2131 
12368 ± 
3128 
11667 ± 
1930 
12383 ± 
2656 
Energy 
excluding 
alcohol / kJ 
8822 ± 
1901 
8266 ± 
1985 
8138 ± 
1734 
11964 ± 
2162 
11210 ± 
1765 
11500 ± 
1245 
Fat / % E 33.5  ± 5.9 31.9 ± 5.6 33.0 ± 4.7 31.6 ± 3.3 30.3 ± 2.9 32.9 ± 2.6 
Protein / %E 14.7  ± 3.1 14.1  ± 2.5 14.3  ± 2.4 13.9 ± 1.8 13.8 ± 1.3 13.6 ± 1.5 
Carbohydrate 
/ %E 
49.0  ± 5.2 49.3 ± 7.2 47.4  ± 7.8 52.4 ± 3.5 53.2 ± 3.6 51.1 ± 3.9 
Alcohol / %E 2.9 ± 4.0 4.7 ± 5.8 5.3 ± 7.9 2.0 ± 6.2 2.8 ± 5.9 2.3 ± 3.7 
 600 
 601 
 602 
 603 
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FIGURE LEGENDS 605 
 606 
FIGURE 1: Postprandial appetite ratings for (A) desire to eat a meal, (B) hunger, and (C) 607 
postprandial breath hydrogen in 13 healthy men and women after consuming a mixed breakfast and 608 
lunch that included inulin (■), L-rhamnose (▲) or control (●) following a 6-day run-in period.  609 
Values are mean with error bars representing the SEM. 610 
 611 
FIGURE 2: Postprandial plasma insulin (A) timecourse curve and (B) incremental area under 612 
curve in 13 healthy men and women after consuming a mixed breakfast and lunch that included 613 
inulin (■), L-rhamnose (▲) or control (●) following a 6-day run-in period.  Values are mean with 614 
error bars representing the SEM.  615 
 616 
FIGURE 3: Postprandial serum (A) propionate, (B) acetate and (C) butyrate in 13 healthy men and 617 
women after consuming a mixed breakfast and lunch that included inulin (■), L-rhamnose (▲) or 618 
control (●) following a 6-day run-in period.  Values are mean with error bars representing the SEM. 619 
 620 
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